PULMONARY ARTERIAL HYPERTENSION
Clinical trials for PULMONARY ARTERIAL HYPERTENSION explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ARTERIAL HYPERTENSION trials appear
Sign up with your email to follow new studies for PULMONARY ARTERIAL HYPERTENSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Novartis halts Mid-Stage trial for rare lung disease treatment
Disease control TerminatedThis study tested whether adding an experimental drug called LTP001 to standard treatments could help people with pulmonary arterial hypertension, a serious lung and heart condition. About 47 participants took either LTP001 or a placebo pill daily for 24 weeks while continuing th…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
PAH drug trial halted early, leaving questions unanswered
Disease control TerminatedThis study aimed to gather more information about the long-term safety and effectiveness of the experimental drug LTP001 for people with pulmonary arterial hypertension (PAH), a serious lung and heart condition. It was designed as a follow-up for 31 people who had completed an ea…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC